LONG-TERM OUTCOMES WITH EMICIZUMAB PROPHYLAXIS FOR SEVERE HAEMOPHILIA A WITHOUT FVIII INHIBITORS: EFFICACY AND SAFETY ANALYSES FROM HAVEN 3 & 4

被引：0
|
作者：
Mahlangu, J. [1 ,2 ]
Jimenez-Yuste, V. [3 ]
Ventriglia, G. [4 ]
Niggli, M. [4 ]
Barlera, S. [5 ]
Hermans, C. [6 ]
Lehle, M. [4 ]
Chowdary, P. [7 ]
Jew, L. [8 ]
Windyga, J. [9 ]
Frenzel, L. [10 ]
Castaman, G. [11 ]
Pipe, S. W. [12 ]
机构：
[1] Univ Witwatersrand, Johannesburg, South Africa
[2] NHLS, Johannesburg, South Africa
[3] Univ Autonoma Madrid, La Paz Univ Hosp, Madrid, Spain
[4] F Hoffmann La Roche Ltd, Basel, Switzerland
[5] Parexel Int, Milan, Italy
[6] Catholic Univ Louvain UCLouvain, Univ Clin St Luke, Brussels, Belgium
[7] Royal Free London, Katharine Dormandy Haemophilia & Thrombosis Unit, London, England
[8] Genentech Inc, San Francisco, CA USA
[9] Inst Hematol & Transfus Med, Dept Hemostasis Disorders & Internal Med, Lab Hemostasis andMetabol Dis, Warsaw, Poland
[10] Necker Enfants Malades Hosp, Dept Hematol, Paris, France
[11] Careggi Univ Hosp, Florence, Italy
[12] Univ Michigan, Dept Pediat & Pathol, Ann Arbor, MI USA
来源：
HAEMOPHILIA | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO135
引用
收藏
页码：95 / 96
页数：2
相关论文
共 50 条
  • [1] Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies
    Callaghan, Michael U.
    Negrier, Claude
    Paz-Priel, Ido
    Chang, Tiffany
    Chebon, Sammy
    Lehle, Michaela
    Mahlangu, Johnny
    Young, Guy
    Kruse-Jarres, Rebecca
    Mancuso, Maria Elisa
    Niggli, Markus
    Howard, Monet
    Bienz, Nives Selak
    Shima, Midori
    Jimenez-Yuste, Victor
    Schmitt, Christophe
    Asikanius, Elina
    Levy, Gallia G.
    Pipe, Steven W.
    Oldenburg, Johannes
    BLOOD, 2021, 137 (16) : 2231 - 2242
  • [2] Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies
    Mahlangu, Johnny
    Jimenez-Yuste, Victor
    Ventriglia, Giuliana
    Niggli, Markus
    Barlera, Simona
    Hermans, Cedric
    Lehle, Michaela
    Chowdary, Pratima
    Jew, Lyle
    Windyga, Jerzy
    Frenzel, Laurent
    Schmitt, Christophe
    Castaman, Giancarlo
    Pipe, Steven W.
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2024, 8 (02)
  • [3] Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies (vol 137, pg 2231, 2021)
    不详
    BLOOD, 2023, 142 (15) : 1329 - 1329
  • [4] Long-term analysis of real clinical practice of emicizumab treatment in patients with severe haemophilia A with and without FVIII inhibitors
    Zozulya, N.
    Dimitrieva, O.
    Yakovleva, E.
    HAEMOPHILIA, 2024, 30 : 122 - 122
  • [5] The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies
    Skinner, Mark W.
    Negrier, Claude
    Paz-Priel, Ido
    Chebon, Sammy
    Jimenez-Yuste, Victor
    Callaghan, Michael U.
    Lehle, Michaela
    Niggli, Markus
    Mahlangu, Johnny
    Shapiro, Amy
    Shima, Midori
    Campinha-Bacote, Avrita
    Levy, Gallia G.
    Oldenburg, Johannes
    von Mackensen, Sylvia
    Pipe, Steven W.
    HAEMOPHILIA, 2021, 27 (05) : 854 - 865
  • [6] SAFETY AND EFFICACY OF EMICIZUMAB IN PERSONS WITH HAEMOPHILIA A WITH/WITHOUT FVIII INHIBITORS: POOLED DATA FROM FOUR PHASE III STUDIES (HAVEN 1-4)
    Callaghan, M. U.
    Negrier, C.
    Paz-Priel, I.
    Chang, T.
    Chebon, S.
    Lehle, M.
    Mahlangu, J.
    Young, G.
    Kruse-Jarres, R.
    Mancuso, M. E.
    Niggli, M.
    Howard, M.
    Bienz, N. S.
    Shima, M.
    Jimenez-Yuste, V.
    Schmitt, C.
    Asikanius, E.
    Levy, G. G.
    Pipe, S. W.
    Oldenburg, J.
    HAEMOPHILIA, 2021, 27 : 126 - 127
  • [7] Real-world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors
    Hassan, Eman
    Jonathan, Lancashire
    Jayashree, Motwani
    HAEMOPHILIA, 2021, 27 (06) : E698 - E703
  • [8] Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors
    Kempton, Christine
    Trask, Peter
    Parnes, Aric
    Niggli, Markus
    Campinha-Bacote, Avrita
    Callaghan, Michael U.
    O'Connell, Niamh
    Paz-Priel, Ido
    Mahlangu, Johnny N.
    HAEMOPHILIA, 2021, 27 (02) : 221 - 228
  • [9] Emicizumab prophylaxis for the treatment of infants with severe haemophilia A without factor VIII inhibitors: primary analysis of the HAVEN 7 study
    Pipe, S. W.
    Collins, P.
    Dhalluin, C.
    Kenet, G.
    Schmitt, C.
    Buri, M.
    Jimenez-Yuste, V.
    Peyvandi, F.
    Young, G.
    Oldenburg, J.
    Mancuso, M. E.
    Kavakli, K.
    Kiialainen, A.
    Niggli, M.
    Chang, T.
    Lehle, M.
    Fijnvandraat, K.
    HAEMOPHILIA, 2024, 30 : 24 - 25
  • [10] Safety and Efficacy of Emicizumab in Persons with Hemophilia a with or without FVIII Inhibitors: Pooled Data from Four Phase III Studies (HAVEN 1-4)
    Callaghan, Michael U.
    Negrier, Claude
    Paz-Priel, Ido
    Chang, Tiffany
    Chebon, Sammy
    Lehle, Michaela
    Mahlangu, Johnny
    Young, Guy
    Kruse-Jarres, Rebecca
    Mancuso, Maria Elisa
    Niggli, Markus
    Kuebler, Peter
    Bienz, Nives Selak
    Shima, Midori
    Jimenez-Yuste, Victor
    Schmitt, Christophe
    Asikanius, Elina
    Levy, Gallia
    Pipe, Steven W.
    Oldenburg, Johannes
    BLOOD, 2020, 136
12345